Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Analysis of the anorectic efficacy of HMR1426 in rodents and its effects on gastric emptying in rats

International Journal of Obesity volume 28, pages 211–221 (2004)Cite this article

Abstract

OBJECTIVES: Pharmacodynamics of HMR1426 in rodents.

SUBJECTS: Male and female rats and male mice.

MEASUREMENTS: 24 h feed consumption was measured. From the time curves IC50 values of HMR1426 were calculated. Microanalysis of feeding behavior was determined. Macronutrient preference was measured, by offering rats three different diets. Gastric emptying was measured after liquid gastric loads or solid meals. In rats with gastric cannulas, milk consumption was measured with closed or open cannulas. Diabetes-related parameters and thyroid hormones were measured.

RESULTS: HMR1426 inhibited feed consumption dose-dependently in rodents. Microstructural analysis of feeding after HMR1426 differed from central acting anorectics. HMR1426 inhibited consumption of fat- and carbohydrate-enriched diets. Gastric empyting was dose- and time-dependently delayed. Gastric emptying correlated with the time course of the anorectic effect. In sham-fed rats, HMR1426 had no anorectic effect with open cannulas. Anorectic effect occurred with closed cannulas. We proved that HMR1426 is not a CCKA agonist.

CONCLUSION: The correlation between anorectic properties of HMR1426 and gastric emptying suggests that gastric emptying may cause the anorectic properties of HMR1426. The differences in microstructural feeding behavior between HMR1426 and centrally active anorectics makes it unlikely that HMR1426 acts via the CNS. Evidence for a peripheral mode of action is derived from sham-fed rats with open gastric fistula. When the milk fed was drained, HMR1426 was ineffective. HMR1426 is not a CCKA agonist. The molecular action of HMR1426 causing gastric emptying and its anorectic properties are under investigation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  1. Mokdad Ali HM, Serdula MK, Dietz WH, Bowmann BA, Marks JS, Koplan JP . The spread of the obesity epidemic in the United States 1991–1998. JAMA 1998; 282: 1519–1522.

    Article  Google Scholar 

  2. Wolf AM, Colditz GA . Current estimates of the economic costs of obesity in the United States. Obesity Res 1998; 6: 97–106.

    Article  CAS  Google Scholar 

  3. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P . Efficay and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord 1998; 22: 32–38.

    Article  CAS  Google Scholar 

  4. McNeely W, Goa KL . Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56: 1093–1124.

    Article  CAS  Google Scholar 

  5. Lucas KH, Kaplan-Machlis B . Orlistat: a novel weight loss therapy. Ann Pharmacother 2001; 35: 314–328.

    Article  CAS  Google Scholar 

  6. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppescharr HP, Krempf M . Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight gain in obese patients. European Orlistat Study Group, Lancet 1998; 352: 167–172.

    Google Scholar 

  7. Bray GA, Greenway FL . Current and potential drugs for treatment of obesity. Endocrine Rev 1999; 20: 805–875.

    Article  CAS  Google Scholar 

  8. Mertens IL, Van Gaal FL . Promising new approaches to the management of obesity. Drugs 2000; 60: 1–9.

    Article  CAS  Google Scholar 

  9. Chiesi C, Huppertz C, Hofbauer KH . Pharmacotherapy of obesity : targets and perspectives. Trends Pharmacol Sci 2001; 22: 247–254.

    Article  CAS  Google Scholar 

  10. World Health Organization. Obesity: preventing and managing the global epidemic: Report of a WHO consultation on obesity, 3rd –5th June Geneva. Switzerland 1977.

  11. Gossel M, Bickel M, Jaehne G, Stapf M, Wandschneider J, Sandow J . Effect of 14 days treatment with HMR1426, a new anorectically acting drug, on body weight development and obesity related serum parameters in Zucker fatty rats. Obes Res 2001; 9 (Suppl): PG72.

    Google Scholar 

  12. Bickel M, Jaehne G, Stapf M, Wandschneider J, Gossel M . Microstructural analysis of feeding behavior after amphetamine, sibutramine and dexfenfluramine in rats (Abstract). Int J Obes Relat Metab Disord 2000; 24 (Suppl 1): A413.

    Google Scholar 

  13. Reynell PC, Spray GH . The simultaneous measurement of absorption and transit in the gastrointestinal tract of the rat. J Physiol 1956; 131: 452–462.

    Article  CAS  Google Scholar 

  14. Erni W, Ritschel A . Effect of temperature of perorally administered phenol red solution on gastric emptying in the rat. Arzneim Forsch/Drug Res 1977; 27: 1043–1045.

    CAS  Google Scholar 

  15. Droppelman DA, Gregory RL, Aplhin RS . A simplified method for assessing drug effects on gastric emptying in rats. J Pharmacol Methods 1980; 4: 227–230.

    Article  Google Scholar 

  16. Asakawa A, Inui N, Ueno N, Makino S, Fujino MA, Kasuga M . Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice. Gastroenterology 1999; 116: 1287–1292.

    Article  CAS  Google Scholar 

  17. Kumara SA, Brawled SP, Boyd E . A permanent gastric fistula. Proc Proc Exp Biol Med 1963; 112: 451–453.

    Article  Google Scholar 

  18. Sachs L . Angewandte Statistik, 4th Ed Springer-Verlag: Heidelberg, Germany; 1974.

    Book  Google Scholar 

  19. Stricker-Krongrad A, Burlet C, Souquet, AM, Courcier S . Sibutramine effects on feeding behavior: a dose-dependency and microstructural analysis. Obesity Res 1995; 3 (Suppl. 4) Abstract 631.

  20. Cerep. (Cell Biology & Receptorology), 128 rue DANTON, 92506 RUEIL-MAIMAISON, France (report: #91) and NOVASCREEN, 7170 Standard Drive, Hanover, Maryland, USA, 21076 (report: T/O 98-3872/3871), 1999-2001. Data on file: Aventis Pharma Deutschland GmbH, D-65926 Frankfurt (M), Germany.

  21. Fink H, Rex A, Voits M . Major biological actions of CCK: a critical evaluation of research findings. Exp Brain Res 1998; 123: 77–83.

    Article  CAS  Google Scholar 

  22. Miller LJ . Gastrointestinal hormones and receptors. In: Yamada T (ed). Textbook of gastroenterology, Vol 1 Lippincott Williams & Wilkins, New York; 1999. pp 35–68.

    Google Scholar 

  23. Hill DR, Singh L, Boden P, Pinnock R, Woodruf GN, Hughes J . Detection of CCK receptors in the CNS. In. Dourish CT, Cooper SJ, Iversen SD, Iversen ll (Eds). Multiple chloecystokinin receptors in the CNS, Chapter 5 Oxford University Press, Oxforf, UK; 1992. pp 57–76.

    Google Scholar 

  24. Henke RB, Willson TM, Sugg EE, Croom DK, Dougherty RW, Queen KL, Birkemo LS, Ervin GN, Grizzle MK, Johnson MF, James MK . 3-(1H-Indazol-3-ylmethyl)-1,5-benodiazepines : CCK-A agonists that demonstrate oral activity as satiety agents. J Med Chem 1996; 39: 2655–2658.

    Article  CAS  Google Scholar 

  25. Hirst CG, Aquino C, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Henke RB, James MK, Johnson MF, Momtahan T, Queen KL, Sherrill RG, Szewcyk J, Willson TM, Sugg EE . Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity: Optimisation of the C3 amino substituent. J Med Chem 1996; 39: 5236–5245.

    Article  CAS  Google Scholar 

  26. Bignon E, Alonso, R, Arone M, Boigerain R, Brodin R, Geudet C, Heaulme M, Keane P, Landi M, Molimars J-C, Olliero D, Poncelet M, Seban E, Simiand J, Soubrie P, Pascal M, Maffrand J-P, Le Fur G . SR 146131, A new potent, orally active, and selective non-peptide cholecystokinin subtype 1 receptor agonist. II: In vivo pharmacological characterization. J Pharmacol Exp Ther 1999; 289: 752–761.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Aventis Pharma Deutschland GmbH, Pharmacology, DI & A. Metabolic Diseases, Frankfurt am Main, Germany

    M Bickel, M Gossel, K Geisen & J Sandow

  2. Medicinal Chemistry, Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany

    G Jaehne & H J Lang

  3. Clinical Discovery & Human Pharmacology, Aventis Pharma Deutschland GmbH, Frankfurt am Main, Germany

    R Rosenburg

Authors
  1. M Bickel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Gossel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Geisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Jaehne
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H J Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Rosenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Sandow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Bickel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bickel, M., Gossel, M., Geisen, K. et al. Analysis of the anorectic efficacy of HMR1426 in rodents and its effects on gastric emptying in rats. Int J Obes 28, 211–221 (2004). https://doi.org/10.1038/sj.ijo.0802540

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0802540

Keywords

This article is cited by

Search

Advanced search

Quick links